Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Asset Writedowns and Impairment: 2009-2025

Historic Asset Writedowns and Impairment for China Pharma Holdings (CPHI) over the last 11 years, with Sep 2025 value amounting to $25,302.

  • China Pharma Holdings' Asset Writedowns and Impairment rose 1627.90% to $25,302 in Q3 2025 from the same period last year, while for Sep 2025 it was $227,467, marking a year-over-year increase of 60.73%. This contributed to the annual value of $450,738 for FY2024, which is 2960.56% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Asset Writedowns and Impairment is $25,302, which was up 1,145.18% from $2,032 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Asset Writedowns and Impairment ranged from a high of $213,379 in Q1 2025 and a low of -$403,601 during Q4 2021.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $4,047 (2023), whereas its average is $31,344.
  • Per our database at Business Quant, China Pharma Holdings' Asset Writedowns and Impairment crashed by 981.94% in 2022 and then skyrocketed by 1,627.90% in 2025.
  • Over the past 5 years, China Pharma Holdings' Asset Writedowns and Impairment (Quarterly) stood at -$403,601 in 2021, then soared by 97.49% to -$10,136 in 2022, then soared by 183.31% to $8,444 in 2023, then tumbled by 256.87% to -$13,246 in 2024, then soared by 1,627.90% to $25,302 in 2025.
  • Its Asset Writedowns and Impairment stands at $25,302 for Q3 2025, versus $2,032 for Q2 2025 and $213,379 for Q1 2025.